Viewing Study NCT05147493

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:58 AM
Ignite Modification Date: 2026-05-14 @ 5:50 AM
Study NCT ID: NCT05147493
Status: UNKNOWN
Last Update Posted: 2022-03-29
First Post: 2021-11-05
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Sponsor: Hellenic Society of Hematology
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
None Renal Impairment View
None Neoplasms, Plasma Cell View
None Neoplasms by Histologic Type View
None Neoplasms View
None Paraproteinemias View
None Blood Protein Disorders View
None Hematologic Diseases View
Keywords: